Antifungal Drug Development and Clinical Trials
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
This contract focuses on the preclinical and clinical development of antifungal medical countermeasures aimed at combating drug-resistant pathogens, specifically targeting Candida auris and Aspergillus species. It involves advancing new treatments through rigorous testing phases to address the growing threat posed by these resistant fungi, which are significant concerns for public health due to their persistence and resistance to current antifungal therapies. Issued by the Department of Health and Human Services under the Biomedical Advanced Research and Development Authority (BARDA), the contract is classified as a subcontract with a NAICS code 541715, which corresponds to research and development in the physical, engineering, and life sciences. The solicitation was posted on May 21, 2026, with responses due by June 21, 2026. Although specific locations of performance and contact points are not disclosed, this initiative underscores the emphasis on innovative pharmaceutical development to enhance the arsenal of medical countermeasures against emerging infectious diseases caused by resistant fungal pathogens.
General Info
Agency
NAICS
Place of Performance
DC, USASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Response Deadline
